Biopharmaceutical companies continue to seek growth opportunities amidst increased focus on specialty pharmaceuticals. Increasing investment across the industry has been seen in scientific innovation (Immuno-oncology, Immunology), rare diseases, precision medicine, new technologies (ADCs, BsAbs, Cell & Gene Therapy), translational medicine and AI- driven drug discovery.
The Biopharmaceutical and MedTech M&A landscapes are shaped by investment cycles, based on macroeconomic factors. However, deal activity continues to drive innovation for new products and operational performance improvement.
Our team brings significant operating and consulting experience across the Biopharmaceutical, MedTech and Private Equity sectors. We advise and partner with clients to assist them in achieving their goals, and performance improvement across the investment continuum from strategy through operational implementation.
We can help with:
We assist various Life Science companies and their investors, including:
- Biopharmaceutical Companies
- MedTech Companies (Devices and Diagnostics)
- Pharmaceutical Services Organizations (CMOs, CDMOs, CROs)
- Board of Directors
- PE Firms
- Activist Investors
- Law Firms (Restructuring, Bankruptcy, Disputes & Investigations, Expert Witness Reports and Testimony)
- Unsecured Creditor Committees
Navigating Global Pharma Policy
November 4, 2025
As the U.S. considers imposing tariffs on European pharmaceutical imports, the ripple effects could be felt across the global healthcare landscape. For an industry already grappling with rising R&D costs and competitive pressures, these tariffs threaten to erode profit margins and disrupt finely tuned supply chains.
CRLs Unveiled: Converting FDA Transparency into a Market Advantage
October 27, 2025
With the FDA’s disclosure of 200 Complete Response Letters (CRLs), leadership teams now have an unprecedented insight into regulatory decision-making to glean patterns, challenge assumptions, and strengthen governance before avoidable failures occur.
What if the biosimilar wave is just a ripple?
September 9, 2025
As biologics face a record-breaking patent cliff, the anticipated biosimilar wave may be more of a ripple than a wave. To thrive, life sciences firms must shift from solely pursuing speed to mastering precision.
ALVAREZ & MARSAL BOLSTERS ITS HEALTHCARE PRACTICE IN SOUTHEAST ASIA (ASEAN) REGION WITH THE APPOINTMENT OF SANATH KUMAR AS MANAGING DIRECTOR
September 1, 2025
Leading global professional services firm Alvarez & Marsal (A&M) has announced the appointment of Sanath Kumar as Managing Director within its Southeast Asia and Australia (SEAA) business unit. Based in Singapore, Mr. Sanath will play a strategic role in building out A&M’s Healthcare and Life Sciences practice across ASEAN markets.
